Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.98 USD
+0.03 (3.53%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.99 +0.01 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Lineage Cell Therapeutics, Inc.'s return on equity, or ROE, is -22.64% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that LCTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LCTX 0.98 +0.03(3.53%)
Will LCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for LCTX
LCTX: Analyst Jason Kolbert from D. Boral Capital Maintains Buy Rating | LCTX Stock News
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business ...
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...
Lineage Cell Therapeutics doses first patient in DOSED study
BlackRock, Inc. Significantly Reduces Holdings in Lineage Cell Therapeutics Inc